TWST Overview

Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.

Wall Street analysts forecast TWST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is41.25 USD with a low forecast of 39.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Twist Bioscience Corp revenue for the last quarter amounts to 110.72M USD, increased 19.31

Twist Bioscience Corp. EPS for the last quarter amounts to -0.71 USD, increased 7.58

Twist Bioscience Corp (TWST) has 979 emplpoyees as of June 17 2026.

Today TWST has the market capitalization of 5.29B USD.